Dzambolat R. Mindzaev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dzambolat R. Mindzaev has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Igor V. Zhirov
E.I. Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
3 shared publications - Sergey Tereshchenko
Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education
3 shared publications - Svetlana N. Nasonova
Chazov National Medical Research Center of Cardiology
3 shared publications - Alexandra A. Korotaeva
Chazov National Medical Research Center of Cardiology
2 shared publications - Elena V. Samoilova
Chazov National Medical Research Center of Cardiology
2 shared publications - Anastasiya E. Lapteva
Chazov National Medical Research Center of Cardiology
1 shared publication
Latest Publications
- Open Access
- 15 November 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (11) , 1389-1394
Pro-inflammatory cytokines in chronic cardiac failure: state of problem
Systemic inflammation is characterized by the induction of pro-inflammatory cytokines, the increased level of which in the blood of patients with chronic heart failure (CHF) correlates with unfavorable clinical outcomes. However, it is unclear whether pro-inflammatory cytokines are the cause or the consequence of the disease progression. CHF with preserved ejection fraction and CHF with reduced ejection fraction demonstrate different inflammatory features, which suggests different degrees of pro-inflammatory pathway activation. The review deals with participation of pro-inflammatory cytokines in pathophysiological processes of CHF development, emphasizing the role of interleukin-6 activation and the effects of accompanying diseases on the course of systemic inflammation. The search for new approaches to prevention and therapy of CHF remains actual. The review presents the results of clinical trials of targeted anti-cytokine therapy which have revealed difficulties in controlling inflammation under the conditions of CHF. Identification of specific pro-inflammatory pathways in CHF pathogenesis will allow one to control inflammatory cascades, thus providing a prospective therapeutic strategy.
- 15 November 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (11) , 1389-1394
Open AccessPro-inflammatory cytokines in chronic cardiac failure: state of problem
Systemic inflammation is characterized by the induction of pro-inflammatory cytokines, the increased level of which in the blood of patients with chronic heart failure (CHF) correlates with unfavorable clinical outcomes. However, it is unclear whether pro-inflammatory cytokines are the cause or the consequence of the disease progression. CHF with preserved ejection fraction and CHF with reduced ejection fraction demonstrate different inflammatory features, which suggests different degrees of pro-inflammatory pathway activation. The review deals with participation of pro-inflammatory cytokines in pathophysiological processes of CHF development, emphasizing the role of interleukin-6 activation and the effects of accompanying diseases on the course of systemic inflammation. The search for new approaches to prevention and therapy of CHF remains actual. The review presents the results of clinical trials of targeted anti-cytokine therapy which have revealed difficulties in controlling inflammation under the conditions of CHF. Identification of specific pro-inflammatory pathways in CHF pathogenesis will allow one to control inflammatory cascades, thus providing a prospective therapeutic strategy.
- Open Access
- 15 September 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (9) , 1066-1072
Prognostic impact of uric acid in patients with acute decompensated heart failure
Aim. To evaluate the prognostic impact of serum uric acid (SUA) on clinical outcomes in patients with acute decompensated heart failure, as well as identify the correlation between hyperuricemia and renal function and diuretic resistance in these patients. Materials and methods. The study included 175 patients (125 men and 50 women) with NYHA class IIIV acute decompensated heart failure. Median age was 64 (5675) years. The Information regarding the survival was obtained 3 years after the admission by telephone calls. Results. 57 patients reached the end point (death from all causes); therefore, all patients were divided into groups: "alive", "dead". The SUA levels did not differ in the groups. The only significant difference in the studied parameters was the estimated glomerular filtration rate (eGFR), which was significantly higher in the "alive" group [70.5 (52.894) and 56 (4079), respectively; p=0.006]. A moderate negative correlation was found between SUA levels and eGFR in the correlation analysis (r=-0.313, p0.001). A comparative analysis showed, that SUA level on admission was significantly higher in patients who subsequently received increased doses of diuretics than in patients with a satisfactory response to standard doses of diuretics [567.8 (479.6791.9) and 512 (422.4619.4), respectively; p=0.011]. Also, higher eGFR level on admission was observed in patients from the normal SUA level group than in patients from the hyperuricemia group [94 (74.5101.5) and 63 (48.881.3), respectively; p=0.002]. Conclusion. We found no significant differences in the uric acid level in patients who reached the end point and those who did not reach it during the three-year follow-up. However, the found correlation between uric acid levels and diuretic resistance calls for further research.
- 15 September 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (9) , 1066-1072
Open AccessPrognostic impact of uric acid in patients with acute decompensated heart failure
Aim. To evaluate the prognostic impact of serum uric acid (SUA) on clinical outcomes in patients with acute decompensated heart failure, as well as identify the correlation between hyperuricemia and renal function and diuretic resistance in these patients. Materials and methods. The study included 175 patients (125 men and 50 women) with NYHA class IIIV acute decompensated heart failure. Median age was 64 (5675) years. The Information regarding the survival was obtained 3 years after the admission by telephone calls. Results. 57 patients reached the end point (death from all causes); therefore, all patients were divided into groups: "alive", "dead". The SUA levels did not differ in the groups. The only significant difference in the studied parameters was the estimated glomerular filtration rate (eGFR), which was significantly higher in the "alive" group [70.5 (52.894) and 56 (4079), respectively; p=0.006]. A moderate negative correlation was found between SUA levels and eGFR in the correlation analysis (r=-0.313, p0.001). A comparative analysis showed, that SUA level on admission was significantly higher in patients who subsequently received increased doses of diuretics than in patients with a satisfactory response to standard doses of diuretics [567.8 (479.6791.9) and 512 (422.4619.4), respectively; p=0.011]. Also, higher eGFR level on admission was observed in patients from the normal SUA level group than in patients from the hyperuricemia group [94 (74.5101.5) and 63 (48.881.3), respectively; p=0.002]. Conclusion. We found no significant differences in the uric acid level in patients who reached the end point and those who did not reach it during the three-year follow-up. However, the found correlation between uric acid levels and diuretic resistance calls for further research.
- Open Access
- 24 March 2021
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 10 (1) , 6-15
Diagnostic prediction models of stratifying chronic heart failure patients based on the underlying disease
Aim. To develop classification criteria for stratifying congestive heart failure (CHF) patients based on the underlying disease.Methods. 61 patients with CHF were recruited in a study. All patients were assigned to three groups according to the underlying disease: patients with coronary artery disease (CAD) (n = 29), patients with arterial hypertension (AH) (n = 19), and those present with dilated cardiomyopathy (DCM) (n = 13). Patients underwent routine clinical examination. Biochemical and inflammatory markers (IL-6, its soluble receptor sIL-6R, and sgp130) were measured in all patients. The Mann-Whitney U test, the Kruskal-Wallis H test, the Pearson χ2 test, and Fischer exact test were used to analyze the selected variables. Discriminant analysis was used for generating prediction models. The quality of the models was evaluated with the ROC analysis.Results. Statistically significant variables identified by the pairwise comparison of patients with CAD and AH, CAD and DCM, AH and DCM were included in the discriminant analysis along with clinically valid parameters. Clinical prediction models of stratifying patients to different etiological groups were based on these parameters. The optimal cut-off values were determined for each model. The area under the ROC curve (AUC) was used to evaluate the quality of the model. The AUC value for CAD and AH groups was 1, for AH and DCM - 72±0.024, and for CAD and DCM - 0.907±0.053.Conclusion. Diagnostic prediction models were developed using the discriminant analysis. These models allow stratifying CHF patients according to the underlying disease (CAD, AH, and DCM). The ROC curves have confirmed the good classifying quality of the models.
- 24 March 2021
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 10 (1) , 6-15
Open AccessDiagnostic prediction models of stratifying chronic heart failure patients based on the underlying disease
Aim. To develop classification criteria for stratifying congestive heart failure (CHF) patients based on the underlying disease.Methods. 61 patients with CHF were recruited in a study. All patients were assigned to three groups according to the underlying disease: patients with coronary artery disease (CAD) (n = 29), patients with arterial hypertension (AH) (n = 19), and those present with dilated cardiomyopathy (DCM) (n = 13). Patients underwent routine clinical examination. Biochemical and inflammatory markers (IL-6, its soluble receptor sIL-6R, and sgp130) were measured in all patients. The Mann-Whitney U test, the Kruskal-Wallis H test, the Pearson χ2 test, and Fischer exact test were used to analyze the selected variables. Discriminant analysis was used for generating prediction models. The quality of the models was evaluated with the ROC analysis.Results. Statistically significant variables identified by the pairwise comparison of patients with CAD and AH, CAD and DCM, AH and DCM were included in the discriminant analysis along with clinically valid parameters. Clinical prediction models of stratifying patients to different etiological groups were based on these parameters. The optimal cut-off values were determined for each model. The area under the ROC curve (AUC) was used to evaluate the quality of the model. The AUC value for CAD and AH groups was 1, for AH and DCM - 72±0.024, and for CAD and DCM - 0.907±0.053.Conclusion. Diagnostic prediction models were developed using the discriminant analysis. These models allow stratifying CHF patients according to the underlying disease (CAD, AH, and DCM). The ROC curves have confirmed the good classifying quality of the models.
- Open Access
- 15 September 2019
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 91 (9) , 62-67
Full - transcriptome analysis of miRNA expression in mononuclear cells in patients with acute decompensation of chronic heart failure of various etiologies
It is known that micro RNAs are an important regulatory element in the pathogenesis of many diseases, including cardiovascular diseases. Different levels of expression of these molecules in various pathologies makes miRNA a potential diagnostic and prognostic biomarker. Aim. Analysis of miRNA expression levels in mononuclear blood cells (MBC) of patients with acute decompensation f chronic heart failure (CHF) of various etiologies and evaluation of the possibility of their use as a biological marker. Materials and methods. 7 male patients with acute decompensation of CHF with a reduced ejection fraction (EF), NYHA functional class II–IV (FC) according to NYHA [mean (M) EF 29.2%, standard deviation (SD) 13.27%] in age 38 to 65 years old [median (Me) 58 years]. In 3 patients, heart failure developed as a result of dilated cardiomyopathy (DCMP), in 4 patients – against the background of post-infarction cardiosclerosis of the ischemic nature [group of patients with coronary heart disease (CHD)]. The control group – 5 age-matched (from 41 to 57 years old, Me 49 years old) healthy male volunteers. A complete transcript analysis of miRNA expression in MNCs was performed for all patients and healthy volunteers. Results. Differentially expressed miRNAs were determined in patients with CHF (regardless of etiology) compared with healthy individuals: miR-182, miR-144, miR-183, miR-486-5p, miR-143 (log2FC >1, FDR p-value Keywords: acute decompensation of chronic heart failure, miRNA, biomarker, diagnostics
- 15 September 2019
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 91 (9) , 62-67
Open AccessFull - transcriptome analysis of miRNA expression in mononuclear cells in patients with acute decompensation of chronic heart failure of various etiologies
It is known that micro RNAs are an important regulatory element in the pathogenesis of many diseases, including cardiovascular diseases. Different levels of expression of these molecules in various pathologies makes miRNA a potential diagnostic and prognostic biomarker. Aim. Analysis of miRNA expression levels in mononuclear blood cells (MBC) of patients with acute decompensation f chronic heart failure (CHF) of various etiologies and evaluation of the possibility of their use as a biological marker. Materials and methods. 7 male patients with acute decompensation of CHF with a reduced ejection fraction (EF), NYHA functional class II–IV (FC) according to NYHA [mean (M) EF 29.2%, standard deviation (SD) 13.27%] in age 38 to 65 years old [median (Me) 58 years]. In 3 patients, heart failure developed as a result of dilated cardiomyopathy (DCMP), in 4 patients – against the background of post-infarction cardiosclerosis of the ischemic nature [group of patients with coronary heart disease (CHD)]. The control group – 5 age-matched (from 41 to 57 years old, Me 49 years old) healthy male volunteers. A complete transcript analysis of miRNA expression in MNCs was performed for all patients and healthy volunteers. Results. Differentially expressed miRNAs were determined in patients with CHF (regardless of etiology) compared with healthy individuals: miR-182, miR-144, miR-183, miR-486-5p, miR-143 (log2FC >1, FDR p-value Keywords: acute decompensation of chronic heart failure, miRNA, biomarker, diagnostics